So, how does Mounjaro work? In short, it mimics two hormones your gut already releases after you eat. Once you know what those hormones do, the medication makes a lot more sense. You don't need a pharmacology degree for this. A few clear steps are enough.
A plain-English look at how Mounjaro works, from the two gut hormones it mimics to the blood sugar and appetite signals they set off.
Two hormones your gut already makes
Both hormones belong to a group called incretins. Your gut releases them after a meal, and they help your body manage blood sugar as food arrives. The first is GLP-1, short for glucagon-like peptide-1. Most of it comes from L cells, which sit mainly in the lower small intestine and the colon.
The second is GIP, short for glucose-dependent insulinotropic polypeptide. It comes from K cells, found mostly in the upper small intestine, closer to the stomach. Those cells sit in different places, so their timing and reach differ a little.
These signals don't stay in the gut. They travel through the bloodstream to the pancreas and to parts of the brain. That lets the body respond to a meal in a coordinated way. GLP-1 levels rise within minutes of eating, which is one reason timing matters in this story. If you want a plain-language primer before going deeper, our OzemPro guide walks through how these medications fit together.
Eating well on GLP-1 doesn't have to be complicated: get a nutrition plan made for your treatment.
Build my planWhat GLP-1 does once it reaches the body
GLP-1 does several jobs at once. First, it helps the pancreas release insulin, but mostly when blood sugar is already high. When glucose drops, that effect fades. The signal follows the situation instead of running nonstop.
Second, GLP-1 tells the pancreas to dial back glucagon. Glucagon prompts the liver to release stored sugar. Less glucagon means less sugar leaking into the blood between meals.
How GLP-1 slows stomach emptying
Third, GLP-1 slows gastric emptying, so the stomach moves food into the small intestine more gradually. That helps explain why people often say they feel full for longer after eating.
Finally, GLP-1 sends signals to the hypothalamus and brainstem, regions involved in appetite and hunger. Those signals can make you feel less hungry. Scientists are still mapping the finer details of how these brain pathways work, so treat this as the general picture.
What GIP does, and why it isn't just a copy of GLP-1
GIP also boosts insulin release after meals, which sounds a lot like GLP-1 on paper. It also acts on fat tissue and affects how the body stores and uses energy. This is where the picture gets less tidy.
Researchers have asked whether GIP's role in fat tissue could be a useful target. Some have wondered whether blocking GIP, rather than activating it, could help with weight. That question is still open. Treat it as research-stage thinking, not settled clinical fact. You can read the debate yourself by searching PubMed for GIP receptor agonism versus antagonism in obesity.
GIP's effect on appetite is also less clear than GLP-1's. Studies do not all agree on how much GIP shapes hunger and fullness. That uncertainty is one reason GIP remains an active area of study.
Why one molecule that hits both receptors matters
Receptors are docking sites on cells, and a hormone or drug fits into them to send a message. Tirzepatide is a single molecule built to fit into two different docking sites, the GIP receptor and the GLP-1 receptor. That's why researchers call it a dual agonist. An agonist switches a receptor on.
Semaglutide, by comparison, is designed to activate only the GLP-1 receptor, according to its labeling. This comparison is about mechanism alone. How the two drugs work at the receptor level is different from how they perform in patients. For head-to-head results, read the SURPASS-2 paper rather than relying on any secondhand summary.
The fatty acid chain and weekly dosing
Tirzepatide carries a fatty acid chain as part of its structure. That chain lets the molecule bind to albumin, a protein that circulates in the blood. Bound to albumin, the drug clears from the body more slowly, which helps it last long enough for once-weekly dosing. The clinical pharmacology section of the prescribing information describes this, and it lists the exact half-life. Check that figure there rather than trusting memory, since labels get updated. If you want to see how weekly dosing works in practice, the OzemPro resource on injection schedules is a practical place to start.
What the clinical trials measured and what they didn't
The SURPASS program studied tirzepatide in type 2 diabetes. The SURMOUNT program studied it for obesity. The key obesity trial is SURMOUNT-1, published by Jastreboff and colleagues in the New England Journal of Medicine in 2022.
When you read a trial result, compare the weight change in the drug group with the change in the placebo group. The drug group alone doesn't tell the full story. Then check how long the trial ran. A few months and a full year can point to very different conclusions.
Trials also report averages. Some participants lost a lot of weight, some lost little, and a few barely changed. Individual results vary. For exact percentages, trial durations, and participant numbers, go straight to the published papers.
Still planning meals by trial and error? Build a nutrition plan tailored to your GLP-1.
Build my planWhat this means for you, and when to talk to a doctor
These mechanisms explain much of what people notice day to day. Slower stomach emptying and signals reaching the brain can make appetite drop and meals feel more filling. Side effects such as nausea are listed in the prescribing information, so review that section before your first dose.
A mechanism explanation doesn't replace medical supervision. Dose changes, eligibility, and whether this medication suits your situation all depend on a clinician who knows your history. Never adjust a dose on your own based on something you read.
Bring a few questions to your next appointment. OzemPro's overview of dosing can help you prepare, but your prescriber has the final say. Consider asking:
- Does Mounjaro fit my health history, including conditions and medications I already take?
- What dose schedule applies to me, and what would prompt a change?
- How will we track progress, and which measures matter most for me?
- Which side effects should make me call the office right away?
Mounjaro is not a cure. Results depend on the full treatment plan, including food choices, physical activity, and follow-up visits. Think of the drug as one part of a larger plan.
FAQ
Does Mounjaro reduce appetite?
For many people it can help reduce appetite, largely through GLP-1 signals to the hypothalamus and brainstem. How much hunger changes varies from person to person.
Why is tirzepatide called a dual agonist?
Because one molecule activates two receptors: the GIP receptor and the GLP-1 receptor.
Does Mounjaro slow stomach emptying?
GLP-1 slows gastric emptying, and tirzepatide acts on the GLP-1 receptor, so it can affect emptying. How that plays out for you is a question for your clinician.
Can I change my dose on my own?
No. Dose changes should be made with a clinician, who can weigh your history, tolerance, and goals first.
Sources
- Mounjaro (tirzepatide) Prescribing Information, Eli Lilly
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2), NEJM 2021
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022
- Holst JJ. The Physiology of Glucagon-like Peptide 1, Physiological Reviews 2007
- Semaglutide labeling, DailyMed (U.S. National Library of Medicine)
- PubMed search: GIP receptor agonism versus antagonism in obesity (U.S. National Library of Medicine)
- PubMed search: incretin biology, GIP and K cells in the upper small intestine (U.S. National Library of Medicine)
Aviso: Este conteúdo é apenas informativo e não substitui orientação médica profissional. Consulte sempre seu médico antes de iniciar, alterar ou interromper qualquer tratamento.
